The Technical Analyst
Sight Sciences, Inc. [SGHT]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Sight Sciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.60% $5.24
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 259.66 mill |
| EPS: | -1.140 |
| P/E: | -4.60 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 49.55 mill |
| Avg Daily Volume: | 0.195 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.60 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -4.60 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.96 - 5.52 ( +/- 5.34%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-03 | Hayden Jeremy B. | Sell | 4 893 | Common Stock |
| 2024-04-03 | Badawi Paul | Sell | 12 571 | Common Stock |
| 2024-04-03 | Badawi David | Sell | 3 128 | Common Stock |
| 2024-04-03 | Park Sam Boong | Sell | 3 414 | Common Stock |
| 2024-04-03 | Bauerlein Alison | Sell | 10 123 | Common Stock |
| INSIDER POWER |
|---|
| -24.25 |
| Last 95 transactions |
| Buy: 4 792 402 | Sell: 8 805 650 |
Forecast:
16:00 - $5.27
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.27
Forecast 2: 16:00 - $5.27
Forecast 3: 16:00 - $5.27
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.24 (-2.60% ) |
| Volume | 0.159 mill |
| Avg. Vol. | 0.195 mill |
| % of Avg. Vol | 81.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SGHT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:32 | buy | $4.51 | N/A | Active |
|---|
SGHT
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-18 16:05:00 - Press Release
Sight Sciences To Report First Quarter Financial Results On May 2, 2024
Menlo park, calif., april 18, 2024 (globe newswire) -- sight sciences, inc. (nasdaq: sght) (“sight sciences” or the “company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended march 31, 2024, after the market close on thursday, may 2, 2024. the company's management will discuss the results during a conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time.
2024-04-10 16:05:00 - Press Release
Sight Sciences Announces The Publication Of Large-scale, Real-world Migs Study Demonstrating The Comprehensive Aqueous Outflow Restorative Procedure With Omni® Surgical System Technology Is Effective At Lowering Both Iop And Iop Reducing Medications At 2 Years In Patients With Glaucoma
The efficacy of the three most commonly used migs technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes the efficacy of the three most commonly used migs technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes
2024-04-02 16:05:00 - Press Release
Sight Sciences Announces The Results Of The Three-year Prospective Gemini Trial And The Cross-over Phase Of The Sahara Rct At The 2024 American Society Of Cataract And Refractive Surgery (ascrs) Annual Meeting
Clinical results demonstrate long-term efficacy of the omni® surgical system for primary open-angle glaucoma and support use of tearcare® technology as a primary treatment for dry eye disease.
2024-03-26 16:05:00 - Press Release
Sight Sciences To Present At The Upcoming 23rd Annual Needham Healthcare Conference
Menlo park, calif., march 26, 2024 (globe newswire) -- sight sciences, inc. (nasdaq: sght) (“sight sciences” or the “company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will present at the upcoming 23rd annual needham healthcare conference being held virtually.
2024-03-07 16:05:00 - Press Release
Sight Sciences Reports Fourth Quarter And Full Year 2023 Financial Results And Initiates Full Year 2024 Financial Guidance
Menlo park, calif., march 07, 2024 (globe newswire) -- sight sciences, inc. (nasdaq: sght) ("sight sciences" or the "company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended december 31, 2023, and initiated financial guidance for full year 2024.
Latest News
2024-04-18 16:05:00 - GlobeNewsWire
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2024-03-26 16:05:00 - GlobeNewsWire
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will present at the upcoming 23rd Annual Needham Healthcare Conference being held virtually.
2024-03-07 22:56:07 - Seeking Alpha
Sight Sciences, Inc. (SGHT) Q4 2023 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Founder & Chief Executive Officer Ali Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Tom Stephan - Stifel David Saxon - Needham & Company Margaret Kaczor - William Blair Operator Ladies and gentlemen, thank you for standing by and welcome to the Sight Sciences Fourth Quarter 2023 Earnings Results. [Operator Instructions] And please be advised that today's conference is being recorded.
2024-03-07 18:51:04 - Zacks Investment Research
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.35 per share a year ago.
2024-02-22 16:05:00 - GlobeNewsWire
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, March 7, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2024-02-21 11:26:09 - Zacks Investment Research
Sight Sciences (SGHT) to Expand in Europe With New Launch
By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.
2023-11-13 15:40:32 - InvestorPlace
5 Risky Stocks to Buy Immediately, According to AI
This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.
2023-11-11 12:38:03 - Seeking Alpha
Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Founder and Chief Executive Officer Ali Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Margaret Kaczor - William Blair Kallum Titchmarsh - Morgan Stanley Thomas Stephan - Stifel Operator Ladies and gentlemen, thank you for standing by. Welcome to the Sight Sciences' Third Quarter 2023 Earnings Results Call.
2023-10-24 16:05:00 - GlobeNewsWire
Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023
MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 7, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2023-09-21 05:11:35 - Benzinga
Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3 - Sight Sciences (NASDAQ:SGHT), Scilex Holding (NASDAQ:SCLX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.